Children younger than 18 months with neuroblastoma tumors tend to have much higher survival rates than older children. Led by Drs. Watt and Dinesh Rakheja, this UT Southwestern study is investigating the metabolism of neuroblastoma tumors with the objective of identifying targetable variances in tumors from younger and older patients.
We are one of the phase I/II COG institutions chosen to participate in an oral ALK-inhibitor trial for a select group of patients with neuroblastoma. Approximately 15% to 20% of patients with high-risk neuroblastoma have ALK mutations within their tumor, and this inhibitor allows for targeted therapy against the neuroblastoma cells, offering a more attractive therapy than chemotherapy alone.